The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo
- 1 April 1987
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 19 (4) , 449-465
- https://doi.org/10.1093/jac/19.4.449
Abstract
The frequency of development of resistance to the fluoroquinolones in vitro was generally low with Escherichia coli (in the order of 10−7 to < 10−9) and high with Pseudomonas aeruginosa (in the order of 10−5 to 10−7). Susceptibility to the fluoroquinolones also decreased after serial transfer in increasing concentrations of the drug. Although the MICs for the resistant E. coli variants were higher than that of the parent organism, they were still susceptible to achievable serum concentrations of all the quinolones except nalidixic acid. On the other hand some of the P. aeruginosa variants selected for resistance were resistant to achievable serum concentrations of all the quinolones. When E. coli pyelonephritis in mice was treated with the fluoroquinolones, difloxacin, A-56620, and ciprofloxacin were more effective than norfloxacin and nalidixic acid in lowering viable bacterial counts in the kidneys. The susceptibility of E. coli isolated from kidneys of mice treated with the quinolones was the same as that of the parent strain. When P. aeruginosa pyelonephritis in mice was treated with the fluoroquinolones an initial reduction in the cell count was seen, followed by an increase in the number of resistant variants. The resistant variants differed in their colony morphology and cell envelope proteins. The levels of resistance for the P. aeruginosa variants ranged from a two-to a 64-fold increase in the MIC.Keywords
This publication has 15 references indexed in Scilit:
- Comparative Evaluation of Recently Developed Quinolone Compounds – with a Note on the Frequency of Resistant MutantsChemotherapy, 1985
- Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classesAntimicrobial Agents and Chemotherapy, 1984
- Norfloxacin: activity against urinary tract pathogens and factors influencing the emergence of resistanceJournal of Antimicrobial Chemotherapy, 1984
- The pharmacokinetics and tissue penetration of norfloxacinJournal of Antimicrobial Chemotherapy, 1984
- In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprimAntimicrobial Agents and Chemotherapy, 1983
- Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genesAntimicrobial Agents and Chemotherapy, 1982
- Antibodies to cell envelope proteins of Pseudomonas aeruginosa in cystic fibrosis patientsInfection and Immunity, 1981
- Nalidixic acid resistance: A second genetic character involved in DNA gyrase activityProceedings of the National Academy of Sciences, 1977
- Resistance to nalidixic acid. A misconception due to underdosageJAMA, 1976
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTJournal of Biological Chemistry, 1951